Anuh pharma Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI depositories regulations. The pharmaceutical company filed the mandatory certificate for the quarter ended 31st March, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Filing Details

The company submitted the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 to both BSE Limited and National Stock Exchange of India Limited on 07th April, 2026. Company Secretary & Compliance Officer Manan Vadhan signed the submission letter, ensuring proper authorization of the filing.

Certificate Confirmation

Bigshare Services Private Limited, serving as the company's Registrar & Share Transfer Agent, issued the confirmation certificate dated 04th April, 2026. The certificate specifically states that no dematerialisation requests for equity shares were received during the period from 01st January, 2026 to 31st March, 2026.

Stock Exchange Information

Anuh Pharma Limited maintains listings on both major Indian stock exchanges. The company trades on BSE Limited under scrip code 506260 and on National Stock Exchange of India Limited under the symbol ANUHPHR in the EQ series.

Company Operations

Anuh Pharma Limited operates with its registered office located at 3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai. The company maintains manufacturing facilities at E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar, reflecting its operational presence in Maharashtra's pharmaceutical hub.

Anuh Pharma Limited has successfully passed a regulatory audit conducted by the European Directorate for the Quality of Medicines & HealthCare (EDQM) at its manufacturing facilities in Maharashtra. The company announced this development through a regulatory filing, highlighting its continued commitment to maintaining international quality standards.

Audit Details and Facility Coverage

The EDQM audit covered three specific manufacturing units operated by Anuh Pharma Limited:

The European Directorate for Quality of Medicines & HealthCare is a leading authority in pharmaceutical quality standards, making this compliance certification particularly significant for the company's operations.

Regulatory Compliance Achievement

The successful audit outcome demonstrates Anuh Pharma Limited's adherence to stringent international quality standards. The company emphasized that this achievement reaffirms its continued commitment to global regulatory and quality compliance standards. Such certifications are essential for pharmaceutical companies seeking to maintain their market presence and expand their reach in international markets.

The compliance status achieved through this audit validates the company's manufacturing processes, quality control systems, and overall operational standards at the Tarapur facilities. This certification ensures that the manufacturing units meet the rigorous requirements set by European regulatory authorities.

Strategic Significance

For pharmaceutical companies like Anuh Pharma Limited, maintaining compliance with international regulatory standards is crucial for business continuity and growth prospects. The successful EDQM audit provides several strategic advantages:

• Validation of manufacturing quality standards
• Enhanced credibility with international partners
• Continued access to regulated markets
• Reinforcement of operational excellence

The company has made this disclosure available on its official website at www.anuhpharma.com , ensuring transparency with stakeholders and regulatory authorities. This successful audit outcome positions Anuh Pharma Limited favorably in terms of regulatory compliance and quality assurance in the pharmaceutical manufacturing sector.